BioSpace News Archive

Pluristyx, Inc. announced an agreement with the Advanced Regenerative Manufacturing Institute | BioFabUSA to manufacture and commercialize Pluristyx’s clinical-grade reprogrammed induced Pluripotent Stem Cells.

Lisata Therapeutics, Inc. today announced that Erkki Ruoslahti, M.D., Ph.D., has decided to retire from its Board of Directors effective today, July 11, 2023.

Eterna Therapeutics Inc. today announced the appointment of Brant Binder and Richard Wagner, Ph.D. to its Board of Directors. Concurrently, Charles Cherington and Nicholas Singer have stepped down from the Board.

Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) today announced positive topline results from the two Phase 3 multicenter, randomized, double-blind, parallel-group, active-comparator and placebo-controlled clinical trials, Minocycline Versus Oracea® in Rosacea-1 (“MVOR-1”) and Minocycline Versus Oracea in Rosacea-2 (“MVOR-2”), evaluating Minocycline Hydrochloride Modified Release Capsules, 40 mg (“DFD-29”) for the treatment of moderate-to-severe papulopustular rosacea in adults.

BioRestorative Therapies, Inc. today announced it has entered into a definitive agreement with several accredited and institutional investors for the sale of 685,033 shares of the Company’s common stock at an offering price of $3.03 per share in a registered direct offering.

Stryker’s navigation system offers surgeons a comprehensive planning and guidance solution for complex cranial procedures.

Omnicell, Inc. today announced it has increased its number of board seats from 9 to 10, and has appointed Kaushik “Bobby” Ghoshal to fill the newest seat as an independent director of Omnicell’s Board of Directors, effective immediately.

CEL-SCI Corporation (NYSE American: CVM) today announced new data from a biomarker analysis of its pivotal Phase 3 study in newly diagnosed locally advanced squamous cell carcinoma of the head and neck (SCCHN) at the American Head and Neck Cancer Society’s (AHNS) 11th Annual International Conference.

Anixa Biosciences, Inc. today announced that the Canadian Intellectual Property Office has issued Canadian Intellectual Property Office has issued Canadian Patent 2,989,807 covering Anixa’s novel Chimeric Antigen Receptor-T cell (CAR-T) cancer treatment technology.

Verismo Therapeutics today announced that Dr. Mala Talekar, MBBS, DABP, DNB has joined the company as Vice President of Clinical Development.